Published in Cancer Immunol Res on July 02, 2015
Immune Checkpoint Inhibitors: A New Opportunity in the Treatment of Ovarian Cancer? Int J Mol Sci (2016) 0.90
Targeting DNA Repair in Cancer: Beyond PARP Inhibitors. Cancer Discov (2016) 0.82
The role of immune checkpoint inhibition in the treatment of ovarian cancer. Gynecol Oncol Res Pract (2016) 0.81
New treatment option for ovarian cancer: PARP inhibitors. Gynecol Oncol Res Pract (2016) 0.80
Update on Poly-ADP-ribose polymerase inhibition for ovarian cancer treatment. J Transl Med (2016) 0.79
Emerging roles of p53 and other tumour-suppressor genes in immune regulation. Nat Rev Immunol (2016) 0.78
PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression. Clin Cancer Res (2017) 0.78
Understanding Resistance Mechanisms and Expanding the Therapeutic Utility of PARP Inhibitors. Cancers (Basel) (2017) 0.77
PARP inhibitors in ovarian cancer: evidence, experience and clinical potential. Ther Adv Med Oncol (2017) 0.76
PARP Inhibitors in Reproductive System Cancers: Current Use and Developments. Drugs (2017) 0.75
Role of CD152 genetic polymorphisms in the susceptibility to breast cancer. Oncotarget (2017) 0.75
Looking beyond the cancer cell for effective drug combinations. Genome Med (2016) 0.75
Update on immune checkpoint inhibitors in gynecological cancers. J Gynecol Oncol (2016) 0.75
Immune checkpoint blockade reveals the stimulatory capacity of tumor-associated CD103(+) dendritic cells in late-stage ovarian cancer. Oncoimmunology (2016) 0.75
Immunotherapy in the Precision Medicine Era: Melanoma and Beyond. PLoS Med (2016) 0.75
The 'Pushmi-Pullyu' of DNA REPAIR: Clinical Synthetic Lethality. Trends Cancer (2016) 0.75
Overcoming Oncogenic Mediated Tumor Immunity in Prostate Cancer. Int J Mol Sci (2017) 0.75
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature (2005) 26.32
The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer (2012) 24.94
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature (2005) 19.13
Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med (2014) 16.83
T cell exhaustion. Nat Immunol (2011) 11.08
Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A (2005) 10.89
Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci U S A (2003) 5.49
Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature (2014) 5.34
Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med (2012) 5.31
The isolation and characterization of murine macrophages. Curr Protoc Immunol (2008) 4.86
Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol (2014) 4.65
Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci U S A (2008) 4.43
Development of a syngeneic mouse model for events related to ovarian cancer. Carcinogenesis (2000) 4.06
Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors. Cancer Res (2012) 3.74
Enhanced induction of antitumor T-cell responses by cytotoxic T lymphocyte-associated molecule-4 blockade: the effect is manifested only at the restricted tumor-bearing stages. Cancer Res (1997) 1.94
Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss. Mod Pathol (2008) 1.90
Therapeutic PD-1 pathway blockade augments with other modalities of immunotherapy T-cell function to prevent immune decline in ovarian cancer. Cancer Res (2013) 1.78
IFN-gamma- and TNF-dependent bystander eradication of antigen-loss variants in established mouse cancers. J Clin Invest (2008) 1.71
Clinical Use of Interferon-gamma. Ann N Y Acad Sci (2009) 1.69
CTLA4 blockade broadens the peripheral T-cell receptor repertoire. Clin Cancer Res (2014) 1.66
Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo. J Immunol (2014) 1.58
Pathogenic T cells have a paradoxical protective effect in murine autoimmune diabetes by boosting Tregs. J Clin Invest (2010) 1.40
Functional characterization of a novel BRCA1-null ovarian cancer cell line in response to ionizing radiation. Mol Cancer Res (2007) 1.40
A mouse model for the molecular characterization of brca1-associated ovarian carcinoma. Cancer Res (2006) 1.28
Single dose of anti-CTLA-4 enhances CD8+ T-cell memory formation, function, and maintenance. Proc Natl Acad Sci U S A (2010) 1.27
Application of a human tumor colony-forming assay to new drug screening. Cancer Res (1985) 1.26
Cytotoxic T lymphocytes block tumor growth both by lytic activity and IFNγ-dependent cell-cycle arrest. Cancer Immunol Res (2014) 1.25
Nanoparticle-mediated delivery of siRNA targeting Parp1 extends survival of mice bearing tumors derived from Brca1-deficient ovarian cancer cells. Proc Natl Acad Sci U S A (2010) 1.20
Hereditary ovarian cancer. Crit Rev Oncol Hematol (2008) 1.14
Poly(ADP-ribose): PARadigms and PARadoxes. Mol Aspects Med (2013) 1.13
Cutting edge: A monoclonal antibody specific for the programmed death-1 homolog prevents graft-versus-host disease in mouse models. J Immunol (2011) 1.13
Poly(ADP-ribose) polymerase-dependent energy depletion occurs through inhibition of glycolysis. Proc Natl Acad Sci U S A (2014) 1.12
BRCA1 and BRCA2 mutations correlate with TP53 abnormalities and presence of immune cell infiltrates in ovarian high-grade serous carcinoma. Mod Pathol (2012) 1.12
IFN-gamma induces apoptosis in ovarian cancer cells in vivo and in vitro. Clin Cancer Res (2003) 1.11
Anti-CD40 antibody induces antitumor and antimetastatic effects: the role of NK cells. J Immunol (2001) 1.10
The Elephant and the Blind Men: Making Sense of PARP Inhibitors in Homologous Recombination Deficient Tumor Cells. Front Oncol (2013) 1.10
Hereditary breast and ovarian cancer susceptibility genes (review). Oncol Rep (2013) 1.08
Structural Implications for Selective Targeting of PARPs. Front Oncol (2013) 1.04
Programmed death ligand-1 over-expression correlates with malignancy and contributes to immune regulation in ovarian cancer. Cancer Immunol Immunother (2013) 1.01
Immunity of human epithelial ovarian carcinoma: the paradigm of immune suppression in cancer. J Transl Med (2013) 1.01
Poly(ADP-ribose): a signaling molecule in different paradigms of cell death. Biochem Pharmacol (2014) 1.00
Tremelimumab (anti-CTLA4) mediates immune responses mainly by direct activation of T effector cells rather than by affecting T regulatory cells. Clin Immunol (2010) 0.99
The anti-tumor activity of anti-CTLA-4 is mediated through its induction of IFN gamma. Cancer Immunol Immunother (2001) 0.98
In vivo imaging and therapeutic treatments in an orthotopic mouse model of ovarian cancer. J Vis Exp (2010) 0.95
Beyond Breast and Ovarian Cancers: PARP Inhibitors for BRCA Mutation-Associated and BRCA-Like Solid Tumors. Front Oncol (2014) 0.94
Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA-Mutant Ovarian Cancer. Clin Cancer Res (2015) 0.91
Role of poly(ADP-ribose) polymerases in the regulation of inflammatory processes. FEBS Lett (2012) 0.87
Immune checkpoint combinations from mouse to man. Cancer Immunol Immunother (2015) 0.87
The immunomodulatory effects of pegylated liposomal doxorubicin are amplified in BRCA1--deficient ovarian tumors and can be exploited to improve treatment response in a mouse model. Gynecol Oncol (2014) 0.78